Clinical Trial News

Prevent Blindness partners with IAPB for World Sight Day focusing on children's vision, hosting events and launching a tool kit with the National Association of School Nurses. The FDA grants Orphan Drug Designation to SKG1108 for retinitis pigmentosa treatment. InMed Pharmaceuticals secures patents for an ocular drug delivery formulation for AMD. A study validates the accuracy of mobile ophthalmology applications like Eye Handbook for vision assessment.

Lisocabtagene maraleucel (liso-cel) improved response outcomes in relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients, with consistent results across high-risk features. Lower tumor burden and fewer prior treatments correlated with better responses. The objective response rate (ORR) and complete response (CR) rates varied by disease characteristics, but overall, liso-cel showed efficacy even in high-risk patients. Inflammatory markers, bulky disease, and lower creatine clearance rates increased the risk of neurological toxicity.

Tryptamine Therapeutics (AU:TYP) announces AGM on Nov 8, 2024, with director nominations closing Sep 27. The biotech firm reports significant progress with TRP-8803 in treating binge eating disorder and explores treatments for fibromyalgia and irritable bowel syndrome.

Recreational drug use triples risk for repeat serious cardiovascular events within one year of hospitalization, according to a study presented at the European Society of Cardiology Congress 2024. The study, involving 1,392 patients, found that 11% tested positive for recreational drugs, with 7% experiencing major adverse cardiovascular and cerebrovascular events (MACCE) at one year, significantly higher among drug users (13% vs. 6%).

Electroacupuncture added to standard antiemetic therapy significantly increased complete protection from chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients receiving highly emetogenic chemotherapy, with a higher rate of complete protection during the delayed stage.

The phase 3 ECHELON-3 study showed that adding brentuximab vedotin to lenalidomide and rituximab significantly improved overall survival (OS), progression-free survival (PFS), and objective response rates (ORR) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who had received at least 2 prior lines of therapy. The triplet regimen resulted in a 47% reduction in the risk of disease progression or death and an ORR of 64.3% vs 41.5% with the doublet. The benefits were consistent across key subgroups, with manageable safety profiles.

Study approved by Fudan University Shanghai Cancer Center (NCT04461990). FUSCC, DUKE, and I-SPY1 cohorts analyzed for breast cancer prognosis and treatment response using DCE-MRI and multiomic data. FUSCC cohort included 466 participants with prognosis information, DUKE 619, and I-SPY1 128. Primary endpoints were relapse-free survival (RFS) and pathological complete response (pCR). Radiomic features extracted and analyzed for prognostic and treatment response prediction.

Maxim Group's Jason McCarthy maintains Buy rating on Unicycive Therapeutics (UNCY) due to the NDA submission for OLC, potential cost savings, and favorable study results. Despite price target reduction due to TDAPA uncertainties, OLC's approval could unlock significant revenue. UNCY's stock has dropped 76.86% over six months.

Emily Jarvie, a journalist with experience in political, business, and scientific reporting, joined Proactive in 2022. Proactive provides global investment news, operating in finance hubs worldwide, focusing on medium and small-cap markets, blue-chip companies, and emerging technologies. The company uses technology to enhance workflows but maintains human authorship for all content.

Preliminary findings from the phase 1b CC-220-DLBCL-001 trial show that combining golcadomide (0.4 mg) with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is well-tolerated and yields high metabolic response rates in previously untreated aggressive B-cell lymphoma patients. The 0.4-mg dose achieved an 88% complete metabolic response rate, with promising 12-month progression-free survival in both overall and high-risk groups. Golcadomide, a first-in-class oral CELMoD agent, demonstrated a toxicity profile similar to R-CHOP and maintained good dose intensity.